



## **Adherium announces appointment of Matt McNamara to the Board; resignation of Professor John Mills**

**Melbourne, Australia – 21 October 2019:** Adherium Limited (“**Adherium**” or the “**Company**”) (ASX: ADR) is pleased to announce that Melbourne-based Mr. Matthew McNamara has joined the Adherium Board as a non-executive director.

Mr. McNamara is currently the Chief Investment Officer and director of BioScience Managers Pty Ltd. Mr. McNamara has over 25 years’ experience in the Healthcare & Medical Sciences sector. After initially being a Molecular Biology Research Assistant, he spent 11 years in sales & marketing and general management with Merck &Co. and Johnson and Johnson Medical Pty. Ltd respectively. He has served as SVP Business Development of eBioinformatics Inc. and was CEO of a Life Sciences Venture Capital Fund, SciCapital Pty. Ltd. Mr. McNamara was also a director at Adherium from 2013 to 2015.

With Mr. McNamara’s appointment, and following over four years’ service as a director and member of both the Audit & Risk Committee and Nomination & Remuneration Committee, Professor John Mills has submitted his resignation.

On behalf of the Company, Chairman Thomas Lynch thanked Professor Mills for his tenure: “John has brought a medical and commercial view to the Board, and has been fully involved in Board business through his membership of both Board committees. We wish him all the best for the future. We welcome Matt back to the Adherium business, and look forward to working with him as we continue to advance following our refocusing.”

**About Adherium (ASX: ADR):** Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 160,000 sold globally. The company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium’s Hailie™ solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it’s time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD. These tools ultimately enable people who live with asthma or COPD to more easily manage their condition alongside their physician. Learn more at [adherium.com](http://adherium.com).